Navigation Links
Study confirms favorable long-term prognosis of epilepsy
Date:6/14/2010

A study conducted by researchers in The Netherlands confirmed that children with idiopathic new-onset epilepsy have a significantly higher rate of remission than those with remote symptomatic epilepsy. Results of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

According to the Epilepsy Foundation, a person is considered to have epilepsy when they have two or more unprovoked seizures. Epileptic syndromes can be either idiopathic (of unknown cause) or symptomatic of underlying brain damage or disease. In general, idiopathic forms have a better prognosis in terms of both seizure control and eventual remission than do symptomatic forms. While epilepsy can begin at any time of life, 50% of all cases are diagnosed before the age of 25 with many having initial onset in early childhood. Currently there are an estimated 326,000 children under the age of 15 with epilepsy in the U.S.

"Knowledge of the long-term outcome of childhood epilepsy is an important factor in treatment decisions," explained study leader Ada Geerts. "The course of epilepsy is in our view important to investigate, because intra- and inter-individual variation may be considerable. Periods of remission and relapse may interchange which may influence our interpretation of the results of prognostic studies, advice to patients, treatment strategies, and timing of referral for surgery."

Researchers indicate it is still largely unknown whether the long-term outcome of epilepsy is determined by its natural course or whether it can be modified by treatment. Whereas outcome in terms of remission or death can be determined easily, the long-range course of epilepsy is more difficult to describe. To address the need for studies with prolonged follow-up in a large cohort of patients, the research team evaluated the course and outcome of childhood-onset epilepsy in 413 children over a 15-year period.

The study commenced in 1988 with the team evaluating 494 children (aged 1 month to 16 years) who were newly diagnosed with epilepsy. The patients were followed for 5 years, and then contacted again by questionnaire 10 years later. A total of 413 responses were received. The mean age at onset of epilepsy was 5.5 years, and the mean age at last contact was 20.8 years. Etiology was idiopathic in 50.8%, remote symptomatic in 27.8%, and cryptogenic in 21.3%. The mean follow up was 14.8 years.

Two hundred ninety-three of 413 subjects (70.9%) had a terminal remission of at least 5 years at the end of the study (61.9% off antiepileptic drugs [AEDs]; 9.0% on AEDs). In contrast, epilepsy remained active in 30% of patients and became intractable in 10%, with the majority of those with active epilepsy or intractability having a non-idiopathic etiology. In patients with a favorable course, idiopathic etiology was predominant, and the mean longest remission during the first 5 years of follow-up was significantly higher than in all other groups. The researchers concluded that AEDs probably do not influence epilepsy course - they merely suppress seizures. Mortality was significantly higher only in those with remote symptomatic etiology.

Geerts concluded, "The long-term prognosis of epilepsy is favorable in the majority of children, especially for those with idiopathic etiology. It remains to be seen whether such a course is influenced by the treatment given, since childhood-onset epilepsy is often a benign self-limiting disorder and treatment proved to be ineffective in those with active epilepsy or intractability."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Study reveals causes of survival disparities based on insurance among rectal cancer patients
2. Uninsured more likely to die from trauma than patients with insurance, study finds
3. New study finds strong association between smoking and flat precancerous polyps
4. Study shows Hodgkin lymphoma survivors lack post-treatment screening for other cancers
5. Genome-wide study identifies factors that may affect vitamin D levels
6. Study finds poor compliance with cirrhosis surveillance recommendations
7. Study finds beta blockers alone more effective for first variceal bleeding
8. Sleep colors your view of the world: Study suggests sleep may restore color perception
9. Video study finds risky food-safety behavior more common than thought
10. Few health reform options would have covered more people at lower cost than new law, study finds
11. Genetic markers could predict prostate cancer in younger men, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications collaborated ... Prevention,” an animated video designed to prevent the next widespread Ebola ... video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and ...
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... Shark Finds and Kevin ... new DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved ... who play in the wet and early morning dew or right after a rain shower, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, serving ... a new charity campaign. As part of their ongoing community involvement program, funds ... belief that children deserve a voice, and in the spirit of neighbors helping ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: